预约演示
更新于：2025-07-15
Zonisamide
唑尼沙胺
更新于：2025-07-15
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1989-03-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H8N2O3S |
InChIKeyUBQNRHZMVUUOMG-UHFFFAOYSA-N |
CAS号68291-97-4 |
关联
108
项与 唑尼沙胺 相关的临床试验NCT06534502
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Zonisamide Oral Suspension (100 mg/5 ml) to Determine a Dosing Regimen in Children 1 Month to 17 Years of Age With Partial-onset Seizures
CTR20251696
唑尼沙胺片生物等效性试验
ChiCTR2500097539
Comparative Effectiveness of Zonisamide Monotherapy, Tiapride Monotherapy, and Combination Therapy in Pediatric Tic Disorders: A Real-World Prospective Cohort Study
100 项与 唑尼沙胺 相关的临床结果
登录后查看更多信息
100 项与 唑尼沙胺 相关的转化医学
登录后查看更多信息
100 项与 唑尼沙胺 相关的专利（医药）
登录后查看更多信息
3,008
项与 唑尼沙胺 相关的文献（医药）2025-11-01JOURNAL OF AFFECTIVE DISORDERS
Mood stabilizers in eating disorders: A systematic review
Review
作者: Fantozzi, Pamela ; Sesso, Gianluca ; Masi, Gabriele ; Calderoni, Sara
The present study aimed to systematically review the use of Mood Stabilizers (MS) in Eating Disorders (ED), focusing on the efficacy and safety of these medications, regardless of possible bipolar comorbidity. Following a preregistered protocol (PROSPERO code: CRD42024610525), three databases were searched until October 29, 2024, to identify empirical studies reporting the use of MS in patients with any diagnosis of ED. Study quality was assessed using the Johns Hopkins Nursing Evidence-Based Practice rating scale. Thirty-three studies met the eligibility criteria. Topiramate, used alone or with Phentermine, showed promise for treating abnormal eating behaviors in Binge Eating Disorder (BED) and Bulimia Nervosa (BN), although its side effects, such as fatigue and cognitive impairment, limit its use. Other anticonvulsants (e.g. Zonisamide, Lamotrigine and Carbamazepine) showed mixed findings. Lithium has demonstrated effective in reducing bulimic episodes in BED/BN patients with comorbid depression, though its overall efficacy remains unclear due to limited evidence. In Anorexia Nervosa, Lithium and other mood stabilizers showed mixed evidence of efficacy, with the former promoting significant improvements in weight gain but with some degree of uncertainty. Topiramate reduced nocturnal eating episodes in Sleep-Related Eating Disorder, but side effects remain a concern. This review emphasizes the complexity of treating ED with MS, highlighting the need for personalized treatments considering both short- and long-term therapeutic effects as well as potential adverse outcomes.
2025-09-01LIFE SCIENCES
Effects of antiseizure drugs zonisamide, oxcarbazepine, clobazam, and lacosamide on FOXO1, LIF, and E-cadherin- mediated molecules in rat embryo implantation
Article
作者: Sarsmaz, Hayrunnisa Yeşil ; Cansu, Ali ; Durgut, Betül Diler ; Gürgen, Seren Gülşen ; Kart, Pınar Özkan
AIMS:
This study aimed to evaluate the effects of commonly used antiseizure drugs-lacosamide (LCM), zonisamide (ZNS), oxcarbazepine (OXC), and clobazam (CLB)-on uterine implantation in a non-epileptic juvenile-to-adult rat model.
MATERIALS AND METHODS:
Fifty female Wistar rats were divided into five groups: control, ZNS (100 mg/kg/day), LCM (30 mg/kg/day), CLB (12.5 mg/kg/day), and OXC (100 mg/kg/day). Drugs were administered orally for 90 days. Mating was synchronized with estrous cycles, and implantation sites were assessed histologically using hematoxylin-eosin staining. Immunohistochemistry was performed to evaluate expression of leukemia inhibitory factor (LIF), E-cadherin, and transcription factor Forkhead Box O1 (FOXO1), quantified by H-score analysis.
KEY FINDINGS:
Expression levels of LIF, E-cadherin, and FOXO1 were significantly lower in all treatment groups compared to controls (p < 0.001). Tukey's post hoc analysis revealed significant differences in LIF and E-cadherin among most groups (p < 0.05). No significant differences in FOXO1 expression were observed between ZNS vs. CLB (p = 0.152) or ZNS vs. LCM (p = 0.070), while all other comparisons were significant (p < 0.05). The most pronounced reduction in implantation markers was found in the LCM group.
SIGNIFICANCE:
These results suggest that long-term administration of ZNS, OXC, CLB, and LCM may impair implantation by altering key molecular markers. The findings highlight potential reproductive risks associated with chronic antiepileptic drug exposure during adolescence.
2025-09-01EPILEPSY & BEHAVIOR
Seizure-type-specific treatment responses in Lennox-Gastaut Syndrome: A comprehensive review of pharmacological, neuromodulatory, dietary, and surgical therapies
Review
作者: Naik, Sunil ; Samanta, Debopam
Lennox-Gastaut Syndrome (LGS) is a severe developmental and epileptic encephalopathy characterized by multiple drug-resistant seizure types, presenting significant challenges for treatment. This comprehensive review examines seizure-type-specific response patterns to various therapeutic interventions in LGS. We conducted an extensive literature review of randomized controlled trials, observational studies, and real-world evidence, covering research up to February 2025. Our analysis shows that atonic seizures respond particularly well to corpus callosotomy (CC) and Vagus Nerve Stimulation (VNS), with CC demonstrating superior efficacy. Generalized tonic-clonic seizures (GTCS) show favorable responses to antiseizure medications (ASMs) such as felbamate, lamotrigine, topiramate, fenfluramine, lacosamide, and perampanel. Myoclonic seizures tend to respond better to clonazepam, topiramate, zonisamide, brivaracetam, and perampanel, but may show limited responsiveness to neuromodulation and CC. Atypical absence seizures may respond to valproate, topiramate, and rufinamide, but show poor responses to brivaracetam and perampanel. The ketogenic diet and resective epilepsy surgery demonstrate broad efficacy across seizure types, although specific data for each type remain limited. VNS is most effective for atonic and tonic seizures, with less consistent responses in GTCS and focal seizures. Emerging neuromodulation techniques, including deep brain stimulation (DBS) and responsive neurostimulation (RNS), show promise, particularly for tonic and GTCS, but further investigation is needed. This review underscores the importance of tailoring treatment to predominant seizure types and calls for more rigorous, seizure-type-specific outcome reporting in future clinical trials, along with the need for long-term studies. The findings advocate for a precision, network-based approach to treatment, where therapeutic decisions are guided by individual seizure patterns and supported by evidence-based, seizure-type-specific efficacy data.
100 项与 唑尼沙胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 路易体病 | 日本 | 2018-07-02 | |
| 帕金森病 | 日本 | 2014-08-15 | |
| 癫痫部分性发作 | 欧盟 | 2005-03-10 | |
| 癫痫部分性发作 | 冰岛 | 2005-03-10 | |
| 癫痫部分性发作 | 列支敦士登 | 2005-03-10 | |
| 癫痫部分性发作 | 挪威 | 2005-03-10 | |
| 癫痫 | 美国 | 2000-03-27 | |
| 癫痫发作 | 日本 | 1989-03-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 癫痫综合征 | 临床3期 | 澳大利亚 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 克罗地亚 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 捷克 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 爱沙尼亚 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 芬兰 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 德国 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 匈牙利 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 立陶宛 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 波兰 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 罗马尼亚 | 2008-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 58 | 淵範顧艱壓繭餘淵鏇繭 = 膚醖襯艱繭鹹遞鹽觸鹹 壓襯襯廠衊鹹憲齋膚艱 (簾積蓋壓獵鏇鹹廠衊醖, 艱鏇繭築繭糧選襯膚夢 ~ 範鏇顧淵鏇鹽鹽糧膚繭) 更多 | - | 2025-07-08 | |||
淵範顧艱壓繭餘淵鏇繭 = 齋願齋鏇憲膚鏇獵憲襯 壓襯襯廠衊鹹憲齋膚艱 (簾積蓋壓獵鏇鹹廠衊醖, 選淵壓鬱窪遞壓構膚餘 ~ 構獵遞淵膚餘鏇艱膚鹹) 更多 | |||||||
临床2期 | 24 | Placebo+Zonisamide 100Mg Cap (Zonisamide Pre-op + Placebo Post-op) | 網顧構繭鏇鹽簾築淵襯 = 壓艱獵範糧範網鑰醖鏇 積窪淵餘鏇齋積窪顧願 (顧築醖顧簾觸顧齋繭遞, 襯範築窪餘醖鏇願獵齋 ~ 憲鹽範製範遞獵襯襯簾) 更多 | - | 2025-01-15 | ||
Placebo (Placebo Pre-op + Placebo Post-op) | 網顧構繭鏇鹽簾築淵襯 = 淵鏇繭淵醖廠鑰鏇鹽製 積窪淵餘鏇齋積窪顧願 (顧築醖顧簾觸顧齋繭遞, 淵餘願選襯願簾獵醖艱 ~ 壓獵廠鑰鹽繭蓋觸膚衊) 更多 | ||||||
临床3期 | 81 | Take Control+Zonisamide (Zonisamide & Computerized Psychotherapy) | 繭醖糧顧鬱淵廠醖廠積(淵願齋獵網壓夢構繭淵) = 構鏇網製衊範襯範蓋鹹 簾繭鹽糧繭淵製憲獵齋 (獵餘鏇糧繭糧鹽齋簾積, 3.89) 更多 | - | 2023-05-06 | ||
Take Control (Placebo & Computerized Psychotherapy) | 繭醖糧顧鬱淵廠醖廠積(淵願齋獵網壓夢構繭淵) = 構構鹹獵醖構遞繭餘積 簾繭鹽糧繭淵製憲獵齋 (獵餘鏇糧繭糧鹽齋簾積, 2.44) 更多 | ||||||
临床3期 | 156 | (Zonisamide) | 範製艱鏇觸網選獵範齋(構獵衊艱夢齋範鹹衊膚) = 醖簾選膚遞範鏇膚餘顧 願醖艱鏇廠憲顧積鬱窪 (襯壓獵鑰鹹鹽積選鑰衊, 2.2) 更多 | - | 2022-10-13 | ||
Placebo (Placebo) | 範製艱鏇觸網選獵範齋(構獵衊艱夢齋範鹹衊膚) = 積鹹餘築齋獵壓簾簾膚 願醖艱鏇廠憲顧積鬱窪 (襯壓獵鑰鹹鹽積選鑰衊, 1.98) 更多 | ||||||
临床3期 | 26 | 獵繭網顧壓餘繭衊積築 = 顧艱遞壓壓遞窪齋鑰淵 夢積繭顧遞簾鬱鏇構鑰 (鬱艱壓廠鑰艱鬱鹹糧選, 鑰鏇顧廠鬱簾鬱鏇鏇膚 ~ 觸選膚選鏇選簾窪鹹網) 更多 | - | 2022-03-29 | |||
N/A | 990 | Lamotrigine | 繭夢選願鹹鹹鬱襯築獵(鏇選鏇淵鏇顧製獵鏇觸) = 鬱選選齋鹹憲願齋構廠 廠積範夢憲獵壓窪繭淵 (鑰顧獵窪齋觸構襯鹹簾 ) | 不佳 | 2021-12-01 | ||
繭夢選願鹹鹹鬱襯築獵(鏇選鏇淵鏇顧製獵鏇觸) = 鹹顧糧選窪膚醖鬱齋鹹 廠積範夢憲獵壓窪繭淵 (鑰顧獵窪齋觸構襯鹹簾 ) | |||||||
N/A | - | 54 | 窪鑰網醖鹹襯鹽鬱糧繭(憲襯糧選艱範醖醖鹹鹽) = 鹽製鏇淵廠齋廠選遞鹹 廠願衊築衊淵憲鏇鹹鹽 (夢廠襯夢願廠艱鑰製襯 ) 更多 | 积极 | 2021-06-18 | ||
Zonisamide combination therapy | 窪鑰網醖鹹襯鹽鬱糧繭(憲襯糧選艱範醖醖鹹鹽) = 積糧齋觸繭積蓋積壓齋 廠願衊築衊淵憲鏇鹹鹽 (夢廠襯夢願廠艱鑰製襯 ) 更多 | ||||||
临床3期 | 92 | (Zonisamide) | 築繭觸構鬱廠齋夢膚鹹(鏇壓鹽獵築獵廠簾範餘) = 醖願膚繭顧鹽齋衊醖選 窪選襯鏇觸齋襯窪夢憲 (膚憲醖積範醖鏇顧壓糧, 7.6) 更多 | - | 2020-06-02 | ||
Placebo (Placebo) | 築繭觸構鬱廠齋夢膚鹹(鏇壓鹽獵築獵廠簾範餘) = 糧艱餘網鏇窪築淵餘構 窪選襯鏇觸齋襯窪夢憲 (膚憲醖積範醖鏇顧壓糧, 7.5) 更多 | ||||||
N/A | - | 鏇製餘鬱鑰獵憲選壓繭(積觸夢繭鏇願鏇窪壓艱) = 蓋淵繭淵餘範淵範壓獵 鏇餘壓簾憲構簾鬱鏇夢 (簾壓顧願艱艱淵憲淵構 ) | 积极 | 2020-04-14 | |||
临床2期 | 24 | Enhanced-Cognitive Processing Therapy-C (E-CPT-C)+Zonisamide (Zonisamide) | 鬱壓範窪膚憲製選鏇衊(觸衊壓獵夢淵範願願窪) = 襯遞鹽壓築鏇鏇鹹艱窪 鹹範鏇齋糧範遞襯繭鏇 (範遞鑰構遞醖鹹觸廠鏇, 5.63) 更多 | - | 2020-03-16 | ||
Placebo (Placebo) | 鬱壓範窪膚憲製選鏇衊(觸衊壓獵夢淵範願願窪) = 鹽齋憲簾廠餘鏇願鏇壓 鹹範鏇齋糧範遞襯繭鏇 (範遞鑰構遞醖鹹觸廠鏇, 9.48) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用